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Alpha2-Adrenoreceptor Status in 
Obsessive-Compulsive Disorder 
Myung A. Lee, Oliver G. Cameron, George N.M. Gurguis, 
Debra Glitz, Charles B. Smith, M. Hariharan, James L. Abelson, 
and George C. Curtis 
Ten patients with obsessive.compulsive disorder (OCD) and 13 normal control subjects 
received intravenous infusions of 2 × 10 -6 g/kg of clonidine and normal saline on separate 
days. Responses to the drug relating to plasma growth hormone (GH), 3-methoxy-4- 
hydroxyphenylglycol (MHPG), heart rate, blood pressure, and several symptoms were 
determined. Additionally, platelet alpha2-adrenoreceptor binding was measured in most 
of the subjects. GH, MHPG, blood pressure, and heart rate responses to clonidine did 
not differ between groups. As expected, patients reported more symptoms than normal 
subjects, and clonidine was sedating for both groups. Patients did not differ from normal 
subjects in the symptom response to clonidine. The maximum number of binding sites 
(Bm~) for tritiated clonidine was significantly greater in OCD patients than in normals. 
This pattern of alpha2-adrenoreceptor status is different than the patterns in major depres- 
sion and p~,lic anxiety. 
Introduction 
Obsessive-Compulsive disorder (OCD) has been considered to be a rare and treatment- 
refractory disorder. However, a recent epidemiological study (Karno et al. 1988) has 
reported that OCD is one of the more prevalent psychiatric disorders (1.2%-2.4%). 
Serotonergic drugs, such as clomipramine (Insel et al. 1983; Zak et al. 1988), fluvoxamine 
(Goodman et al. 1989), and fluoxefine (Turner et 81. 1985; Jenike et al. 1989), have been 
reported to be effective in the u~eatment of OCD. The effectiveness of serotonergic drugs 
has led to the serotonergic hypothesis of OCD (Zohar et al. 1987). Other biological studies 
also support the significant role of serotonin in OCD (Zohar ~nd lnsel. 1987; Zohar et 
al. 1987; Hollander et al. 1988). 
Prior studies have indicated that adrenergic abnormalities, including alpha adrenore- 
ceptor (Cameron et al., 1984; Roy-Byrne and Uhde. 1985; Albus et al. 1986; Charncy 
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et al. 1989; Sevy et al. 1989) and beta adrenoreceptor (Lima and Turner 1983; Albus et 
al. i986; Brown et al. 1988) binding abnormalities, as well as abnormal res,rmnses to 
infusions of alpha2 adrenergic drugs (Charney et al. 1984; Siever et al. 1985; Chamey 
and Heninger 1986; Uhde et al. 1986; Nutt 1989) and beta adrenergic drugs (Nesse et 
al. 1984), may be present in panic anxiety and generalized anxiety disorder; however, 
not all studies have observed differences (Nutt and Fraser 1987; Norman et al. 1987; 
Stein and Uhde 1988; Schittecatte et al. 1988; Uhde et al. 1989). Similar abnormalities 
of beta adrenoreceptor binding parameters (Extein et al. 1979; Pandey et al. 1979; Mann 
et al. 1985; Wood et al. 1986; Carstens et al. !987) and responses to adrenergically active 
drugs (Matussek et al. 1980; Checkley et al. 1981; Chamey et al. 1982; Siever and Uhde 
1984; Siever et al. 1985; Nutt and Cowan 1987; Amsterdam et al. 1989), but not of 
alpha2 adrenoreceptor binding (Cameron et al. 1984; Katona et al. 1987; Sevy et al. 
1989), have been observed in major depressive disorder. Individuals with both depression 
and panic appear to have alpha2-adrenoreceptor binding similar to panic patients (Grunhaus 
1988; Grunhaus et al. in press). Thus, there is evidence of adrenergic dysfunction in 
some of the anxiety disorders as well as in major depression. 
Unlike studies of serotonergic activity in OCD, and in contrast to studies in other 
anxiety disorders, studies of adrenergic function in OCD are few and results are conflict- 
ing. Siever et al. (1983) have reported blunted plasma growth hormone (GH) responses 
to clonidine, an alpha2-adrenoreceptor agonist. As clonidine appears to increase GH 
release via postsynaptic receptor stimulation (Eriksson et al. 1982), the results of Siever 
et al. (1983) suggest that postsynaptic alpha2-adrenoreceptor sensitivity is decreased in 
OCD. In addition, Hollander et al. (1988) have reported a significant reduction in ob- 
sessions in response to clonidine infusion. However, Rasmussen et al. (1987) reported 
no significant effect of yohimbine, an alpha2-adrenoreceptor antagonist, on OCD symp- 
toms, and no difference in the plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) re- 
sponse to yohimbine between OCD patients and normal subjects. 
In order to clarify the role of adrenergic mechanisms in OCD, we attempted to replicate 
the previously reported abnormal GH response to clonidine in these patients. We also 
evaluated the MHPG, heart rate, blood pressure, and symptom responses to clonidine in 
the same individuals. Finally, we determined platelet alpha2-adrenoreceptor binding in 
some of the same subjects who received the clonidine challenge. 
Methods 
Subjects 
Ten patients with OCD (5 men, 5 women, mean age 33.6 ± 10.0 years, mean duration 
of illness 8.1 +__ 16.6 years) and 13 normal subjects (7 men, 6 women, mean age 32.7 
___ 10.0 years) were studied. All patients met DSM-IH criteria (American Psychiatric 
Association, 1980) for OCD. None had other Axis I diagnoses known to be associated 
with a blunted GH response to clonidine, including major depression (Matussek et al. 
1980; Cheekley et al. 1981; Charney et al. 1982; Siever and Uhde 1984), panic disorder 
(Charney and Heninger 1986; Uhde et al. 1986; Nutt !989), or alcohol dependence 
(Matussek et al. 1984). No normal subject reached criteria for any DSM-III Axis I disorder. 
A semistructured psychiatric interview was used for diagnostic evaluation of all subjects. 
Medical history, physical examination, and screening laboratory studies were used to 
insure that all subjects were medically healthy and were drug free for at least 2 weeks 
before testing. Female subjects were studied within the first 10 days of the menstrual 
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cycle; no menopausal women were studied. Only one of the patients was hospitalized at 
the time of study. Subjects with regular alcohol consumption equivalent to, or greater 
than, an average of four cans of beer per week were excluded. All subjects gave written 
informed consent. 
Procedure 
All subjects were studied twice on separate days; no more than 7 days separated the first 
and second infusions for any subject. On one of the days an active drug was administered, 
on the other, a saline "placebo." Subjects were told that the infusion order was random. 
However, to avoid "breaking the blind" (intravenous clonidine is very sedating), all 
subjects except one received the saline infusion first. 
All subjects were admitted to the University of Michigan Medical Center Ciinical 
Research Center the night before each study day, and remained in bed after midnight 
other than for brief bathroom use. All subjects fasted from midnight. At 8 AM, a 21- 
gauge "beparin lock" needle was inserted into an antecubital vein. Baseline blood samples 
were collected 60 and 75 min after needle insertion. After the 75-rain blood sample, 
either 2 Ixg/kg (2 × 10 -6 g/kg) of clonidine in 10 ml of normal saline, or 10 ml of saline 
("placebo") was administered intravenously over 10 rain. Additional blood samples were 
collected at 15, 30, 45, 60, 90, 120, and 180 rain after infusion. Blood pressure, heart 
rate, and symptom ratings were obtained at the times of each blood sample. Symptom 
ratings were analog measures, from 0 ("none") to 9 ("most ever"). The symptoms rated 
included "sad," "confused," "worded," '~nse," "tired," "feeling good," "panic," "drowsy," 
"fatigue," "dizzy," "headache," "dry mouth," and "nausea"; the state portion of the 
Spielberger State-Trait Anxiety Inventory (STAI; Spielberger et al. 1969) was also com- 
pleted at each of these times. Ratings for "obsessions" and "compulsions" ,~ould have 
been highly desirable, but we were not convinced that analog scales for such complex 
symptomatology would be valid or even reliable; thus, they were not included. For 8 of 
the OCD patients and 7 of the normal controls, blood samples for piatelet alpha2-adren- 
oreceptor binding assays were obtained at the time of the 60-rain baseline sample. 
Biochemical Assays 
For measurement of plasma GH and MHPG, 7-ml blood samples were collected into 
tubes containing beparin and EDTA. Plasma was separated and frozen at -g0°C until 
assay. Plasma GH was measured by radioimmunoassay, and plasma MHPG was measured 
by HPLC with our previously published method (Haribaran et al. 1989). 
Platelet membrane alpha2-adrenoreceptor binding assays were performed by our pre- 
viously published method (Gareia-Sevilla et al. 1981). The maximum number of binding 
sites (B~u) and apparent dissociation constant (KD) were determined for the specific 
binding of tritiated clonidine~ a specific partial agonist, and for tritiated yohimbine, a 
specific antagonist, to fresh (never-frozen) platelet membranes. Specific binding was 
approximately 85% for clonidine and 90% for yohimbine. 
Data Analysis 
Values for each dependent variable at each time point on the ¢lonidine day ~inus the 
same values on the saline "placebo" day (difference scores) were used for dat~. analysis 
of the clonidine challenge data. A profile analysis, a multivariate analog of a between- 
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Figure 1. Means and standard errors of the means for plasma growth hormone (GH) levels (ng/ml) 
at 15 and 0.5 rain before, and 15, 30, 45, 60, 90, 120, and 180 min after intravenous infusion of 
2 p,g/kg (2 × 10 ~ g/kg) of clonidine, for patients with obsessive-compulsive disorder (OCD) and 
for normal subjects. GH d_ata were calculated for each subject at each time point as the difference 
between the GH level after clonidine minus the GH level obtained at the same time after admin- 
istration of a saline "placebo" infusion, given on a separate day. The solid line represents normal 
subjects and the dotted line represents patients. Both groups demonstrated a significant GH increase 
in response to clonidine; no difference between groups was observed. 
within repeated-measures analysis of variance (ANOVA) (Harris 1975), was performed 
for each dependent variable for OCD patients versus normal subjects. For clarity of 
interpretation of results, the heart rate, and the symptom data, separate profile analyses 
of the actual values on the two study days were also performed and reported if significant. 
Receptor binding data from OCD patients were compared with normal subjects with the 
Kruskai-Wallis ANOVA for ranked data. Pearson product-moment correlations were 




In all subjects, plasma GH increased significantly in response to clonidine (profile analysis 
of difference scores, F = 5.59, p = 0.004). Peak responses to 2 [~g/kg of intravenous 
clonidine for both groups occurred at 45 rain postinfusion; levels returned to baseline 
within 120 rain. For all subjects, clonidine increased GH an average of 8.5 ng/ml above 
the average baseline level of 2.7 ng/ml. This increase was approximately 120% of the 
increase (approximately 7.0 n~ml) reported in 22 normal subjects in response to 1.5 
p.g/kg of intravenous clonidine (Nutt and Glue 1988). There was no difference in GH 
response in patients versus normal subjects (Figure 1). Peak GH response (highest level 
attained at any post-clonidine sampling time) and mean GH level at 30, 45, and 60 rain 
post-clonidine for OCD patients, but not for normal subjects, were significantly negatively 












r j  
o,] 
0.0" 
-0 .2"  
-0 .4 -  
-0 .6"  
! t 1 
o l 
-0 .8  . . . . .  
- 2 0  20 60 100 140 180 
TIME 
Figure 2. Means and standard errors of the means for plasma 3-methoxy-4-hydroxyphenylglyco! 
(MHI~) (ng/ml) after clonidine. Details are the same as in Figure 1. No significant group difference 
was observed. There was a strong trend (p = 0.06) for clonidine to produce a significant decrease 
in MHPG. 
correlated with a subjective rating of perceived stress for the 6 months prior to study 
(r ffi - 0.84, t = 4.15, p - 0.004, and r = - 0.83, t -- 3.93, p -- 0.006, respectively). 
In other words, higher stress ratings were associated with greater blunting of the GH 
response. 
There was a trend towards a significant decrease in MHPG in response to clonidine 
for both groups (profile analysis of difference scores, F = 2.69, p = 0.06). No difference 
between groups was observed (Figure 2)  
By profile analysis of difference scores, large and significant decreases in response to 
clonidine were observed for both systolic (F - 10.5, p - 0.0001) and diastolic (F = 
6.85, p = 0.001) blood pressures (not shown); the average maximum decreases were 
17.3 mm Hg systolic at 90 rain postinfusion (t = 5,12, p < 0.0001) and 13.5 mm Hg 
diastolic at 45 rain postinfusion (t -- 6.27, p < 0.0001). For both systolic and diastolic 
pressures, substantial decreases were observed within 15 min postinfusion, which persisted 
throughout the 3-hr session. No difference between groups was observed. 
Normal subjects had a lower mean heart rate than patients with OCD by approximately 
six beats per min on both days (not shown); this was significant for the saline placebo 
day (profile analysis of placebo data, F = 3.01, p = 0.03). Clonidine produced small 
mean decreases in heart rate of less than four beats per min at each time point for both 
groups. Patients and normal subjects were equally sensitive to the clonidine effect on 
heart rate. 
Normal subjects had low mean symptom levels (less than 2.0 for all symptom vari- 
ables at all time points), except for "feeling good" (>7.0) and the STAI (<28, range 
of possible scores is 20-80), on the placebo day; levels were comparably low on the 
clonidine day for all variables except "tired" (<3.0), "drowsy" (<4.5), "fatigue" (<2.5), 
and "dry mouth" (<3.0). On the placebo day, symptom scores were significantly higher 
(profile analyses of placebo data) for patients than for normal subjects for "sad" (peak 
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level 3.6, F = 16.0, p = 0.0006), "worried" (peak 4.7, F = 20.79, p < 0.0002), 
"tense" (peak 3.3, F = 16.3, p = 0.0005), "fired" (peak 4.8, F = 10.1, p = 0.004), 
"fatigue" (peak 4.1, F = 8.28, p = 0.009), "headache" (peak 3.0, F = 4.72, p = 
0.04), and the STAI (peak 49, F = 79.7, p < 0.0001), and significantly lower for 
"feeling good" (peak 4.9, F = 22.1, p = 0.0001). On the clonidine day, levels for 
patients remained significantly higher (by profile analyses of clonidine deta) for "wor- 
ried" (peak 2.6, F - 10.6, p = 0.004), "tense" (peak 2.0, F = 6.51, p = 0.02), 
"tired" (peak 5.3, F = 4.95, p = 0.04), and for the STAI (peak 45, F = 38.8, p 
= 0.006), and remained lower for "feeling good" (peak 5.8, F = 9.12, p = 0.006), 
but was no longer significantly different for "sad," "fatigue," or "headache." Addition- 
ally, after clonidine, but not after placebo, "confused" was significantly higher for pa- 
tients (peak 2.4, F = 5.09, p = 0.03). Based on all subjects (profile analyses of 
difference scores), clonidine produced increases in "tired" (F = 4.34, p = 0.008) and 
"drowsy" (F = 5.08, p = 0.004). For patients, on the placebo day, "worried" and 
"tense" demonstrated a pattern of monotonic decrease over time, whereas on the clon- 
idine day there was a pattern first of increasing then decreasing scores; thus, despite 
the sedative effects, clonidine demonstrated no clear tension-reducing effect. (Results 
of profile analyses for the difference scores for the symptom variables agreed with the 
above results.) In summary, OCD patients reported substantial symptomatology on both 
days, and clonidine produced the expected sedative effect in both subject groups; nor- 
mal subjects reported few symptoms other than sedation, and there was no clear-cut 
difference between patients and normal subjects in the effects of clonidine on symptom 
levels. Clonidine did not produce tension reduction in the patients. 
The mean scores for the Carroll Rating Scale for Depression were significantly higher 
for the patients than for the normal subjects on both the placebo day (14.8 versus 1.3, 
Kruskal-Wallis statistic = 11.4, p = 0.0007) and the clonidine day (13.2 versus 1.1, 
Kruskal-Wallis statistic = 6.48, p = 0.01). These scores, however, are substantially 
lower than those observed in people with primary depression (Carroll et al. 1981; 
Feinberg et al. 1981; Nasr et al. 1984). The mean scores for the trait portion of the 
STAI, for normal subjects and patients respectively, were 29.2 versus 54.4 (Kruskal- 
Wallis statistic = 12.6, p = 0.0004) on the placebo day, and 26.5 versus 47.5 (Krus- 
kal-Wallis statistic = 9.71, p = 0.002) on the clonidine day. These scores are com- 
parable with the published levels for nonpatient populations and for psychiatric out- 
patients (Spielberger et al. 1969). 
Platelet Membrane Binding 
Age and gender ratios did not differ significantly between the patients and normal sub- 
jects who had the receptor assays. The maximum number of binding sites (Bm~) for the 
binding of the agonist tritiated clonidine to platelet alpha2-adrenoreceptors was signifi- 
cantly greater (Kruskal-Wallis statistic = 4.10, p = 0.04) in patients with OCD than 
in normal subjects (Table 1). The Bmax for binding of the antagonist tritiated yohimbine 
was also greater in patients, but this difference did not reach statistical significance. 
Clonidine and yohimbine dissociation constants (KD) did not differ between groups. 
Correlations were performed, including the various physiological dependent variables 
in the clonidine challenge protocol and the platelet-binding parameters. No robust cor- 
relations or patterns of correlations among variables emerged. 
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Table 1. Platelet Alpha2-Adrenoreceptor Binding Results in Patients with Obsessive-Compulsive 
Disorder (OCD) and in Normal Controls 
OCD (n = 8) Normals (n = 7) 
Clonidine Bmax (fmol/mg protein) ~ 41.3 .4- 17.2 29.1 _ 9.48 
Yohimbine Barn (fmol/mg protein) 146 --- 87.3 ! I 1 -+ 39.4 
Clonidine KD (riM) 8.90 ~ 6.80 5.17 ± 2.34 
Yohimbine KD (nM) 2.32 ± 0.45 2.36 -4- 0.78 
ap ffi 0.04 for OCD patients versus norm~ ~u~¢ts by Kruskal-Wallis ANOVA for ranked data. 
Discussion 
Patients had higher scores than normal subjects on several of the symptom ratings on 
both of the study days. Nevertheless, none of the physiological dependent variables in 
the clonidine challenge protocol (GH, MHPG, heart rate, and systolic and diastolic blood 
pressure) differentiated patients with OCD from normal subjects on either study day, and 
there was no difference in the symptom response to clonidine between patients and normal 
subjects. In contrast to the lack of difference between groups for the clonidine infusion 
protocol variables, the maximum number of platelet binding sites (Bm~ for the alpha2- 
adrenoreceptor partial agonist tritJated clonidine was significantly greater ia patier~ts than 
in normal subjects, and there was a nonsignificant increase for the Bm~ for the antagonist 
tritiated yohimbine. Because of the sample size, the binding data resuRs should be 
considered preliminary. 
The results of this study differ from those of Siever et al. (1983). In their study, the 
GH response to the same dose of clonidine was blunted in OCD patients. Additionally, 
in the prior study, pre-clonidine MHPG levels showed a trend to be greater for patients 
than for normal subjects; this increase was not observed in the present study. Finally, in 
the prior study, pre-clonidine norepinephrine levels (which were not measured in the 
present study) were also higher in the patient group. 
It is not certain why there were differences between the results of our study and that 
of Siever et al., but some possibilities are apparent. First, even though the difference 
was not significant, the mean pre-clonidine GH level for patients in the prior study was 
180% of the mean for normal subjects, a difference that did not occur in the present 
study. Second, subjects in the prior study had only one experimental session, whereas 
all subjects in the present study had the experience of having the experimental procedure 
twice; with the exception of one subject, the first of these sessions was with saiine and 
the second was with clonidine. It is possible that a novelty and/or anxiogenic effect of 
the first experimental session interacted with the effects of the clonidine infusion to produce 
a blunted response in the prior study (in the present study, by paired t-tests in the patient 
group, only there were trends for the symptom variables "worried" and "tense" to be 
higher immediately prior to infusion on the first study daymfor both, 0.05 < p < 0.10). 
Third, although the prior investigators did exclude subjects with depressive disorder, they 
do not state whether or not subjects were excluded for the presence of other anxiety 
disorders or for moderate alcohol use. Fourth, it is not known what drug-free time period 
is actually necessary to guarantee that residual psychotropic drug effects are not occurring; 
possibly, unidentified differences between the studies in the drug-free period could have 
had an effect on outcome. And, last, as noted above, in this study, patients who rated 
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themselves as most "stressed" during the previous 6 months demonstrated the most 
blunting of the GH response. Thus, even though the OCD patients as a group did not 
demonstrate a blunted GH response, it is possible that a subgroup of highly "stressed" 
patients (the most symptomatic with OCD?) do show some blunting. If the patients in 
the study by Siever et al. were more "stressed," a difference in study outcome could be 
accounted for. Resolution of these questions awaits further study. Our results appear to 
be in agreement with those of Rasmussen et al. (1987) who found no difference between 
vormal subjects and OCD patients in MHPG changes in response to challenge with the 
antagonist yohimbine, and with Hollander et al. (1989) who reported no blunting of the 
GH response to clonidine in OCD patients. 
As described above, blunted GH responses to clonidine are well docu~-ae~ted in both 
major depression and panic anxiety. Additionally, the GH response to growth hormone- 
releasing factor is blunted in panic patients (Rapaport et al. 1989). In major depression, 
the number of platelet alpha2-adrenoreceptor binding sites is normal or increased, de- 
pending at least in part on whether an agonist or an antagonist ligand is used (Cameron 
et al. 1984; Katona et al. 1987; Sevy et al. 1989). In panic anxiety, the number of sites, 
as measured with tritiated clonidine or yohimbine, is normal or decreased (Cameron et 
al. 1984; Albus et al. 1986; Nutt and Fraser 1987; Charney et al. 1989). Based on these 
prior studies, and assuming that the results of the present study are correct (i.e., the GH 
and MHPG responses to clonidine infusion are normal, and tritiated clonidine binding is 
increased), it appears that the status of the alpha2-adrenoreceptor is different in OCD than 
in either of these other disorders. 
Differences in the patterns of abnormalities in the GH response to clonidine versus in 
the magnitude of platelet binding across different diagnostic groups (depressed, anxious, 
and normal individuals) suggests that the platelet and the hypothalamus have different 
populations of alpha2-adrenoreceptors, as has been suggested previously (Hamilton and 
Reid 1986). Alternatively, another abnormality (instead of, or in addition to, the pre- 
sumptive alpha2-adrenoreceptor abnormality) might be present at some other point(s) in 
the central nervous system (CNS)--pituitary pathway(s) mediating the clonidine-stimu- 
lated GH response. The meaning of the platelet and the hypothalamic alpha2-adrenore- 
ceptor abnormalities for the pathophysiologies of these psychiatric disorders is not yet 
known. 
The authors gratefully acknowledge the technical and nursing staffs of the University of Michigan Medical 
Center Clinical Research Center for their assistance in the completion of this study. 
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